ClinicalTrials.gg
RecruitingNCT06130423MUSMOKHEALTHUpdated Mar 1, 2024

Study to Evaluate Music Therapy and Nicotine Replacement Therapy on Craving Related to Smoking Cessation in Health Staff

An interventional study of Music intervention and Nicotine replacement in Smoking Cessation, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.

Planned enrollment
31st of 43
50 · median 124
Started
2024
with 1 other
No phase
21 of 48
7 open now
Primary completion
2025-01
later than 0 of 10 live
Registered
42nd of 48
by date
Lead sponsor
3 of 48
Poitiers University Hospital

Among the 48 studies in Smoking Cessation with a site in France, this one is the 31st largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 42nd registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Smoking Cessation with a site in France, or all of them as a file.
02

Study summary

The study is a randomized, controlled trial comparing music therapy associated to NRT versus NRT alone to evaluate the value of music therapy in improving the management of craving among 50 health staff smokers. This pilot multi-method study will combine the methodology of clinical trial with qualitative techniques used in social sciences to show the interest of a digital music therapy tool, adapted to a health staff audience.

Read the detailed description

The participants will be recruited at the Clinical Investigation Center (CIC) of the University Hospital of Poitiers. At baseline visit, they will be randomly 1:1 assigned to receive either music therapy and NRT or NRT alone for 3 months.

During the 3 months after Target Quit Date (TQD) , 3 visits will be performed by practitioners and nurses at the CIC. They will register smoking status of the participant, exhaled carbon monoxide concentration, body weight and all adverse events. Participants will answer questionnaires (FTCQ-12,Hospital Anxiety and Depression Scale ( HAD), Minnesota Nicotine Withdrawal Scale (MNWS), Impulsive Behavior Scale (UPPS), State-trait Anxiety Inventory Forme Y (STAI-Y)).

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • Prevention
  • Music Therapy
  • Craving
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health staff,
  • Age >= 18 years
  • Smoking more than 10 cigarettes per day for at least 6 months
  • motivated to quit smoking
  • without legal tutors or subordination
  • affiliated to a health insurance system as required by the French law on biomedical research
  • written for participation in the study

Exclusion criteria

Exclusion Criteria:

  • Roommates and couples
  • NRT
  • unstabilised depression
  • psychosis and/or cognitive disorder and/or mental retardation
  • substance misuse or alcohol dependence
  • smoking-cessation medication (NRT, bupropion) or undergoing cognitive-behavioral therapy or hypnotherapy for smoking cessation in the last 3 months
  • electronic cigarette for smoking cessation in the last 3 months
  • participating in a study up to visit 4
  • Persons benefiting from enhanced protection, i.e.persons deprived of their liberty by a judicial or administrative decision, adults under legal and finally patients in a vital emergency situation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Music intervention and NRT

    The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in th third month, music intervention will be associated to NRT.

    Drug: Music intervention · Drug: Nicotine replacement

  • Active comparator
    NRT Group

    Nicotine Patch, Nicotine Gum as in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.

    Drug: Nicotine replacement

Interventions

  • DrugMusic intervention

    Music therapy carried out with Music Care

  • DrugNicotine replacement

    NRT: Nicotine Patch, Nicotine Gum

06

What researchers measure

Primary outcomes

  1. Assess if Music therapy associated to NRT decrease tabacco craving compared to NRT alone

    Score of French Version of the Tabacco Craving Questionnaire-12 (FTCQ-12). It consist of 12 questions, each rated on a likert-type scale with 7 response options. Lower scores mean a better outcome

    Time frame: Month 1

Secondary outcomes

  1. Test the feasibility of such a program in smoking cessation

    Music therapy sessions compliance. Number and reasons for non attending music therapy sessions

    Time frame: Month 3

  2. Evaluate the evolution of tabacco craving

    Score of French Version of the Tabacco Craving Questionnaire-12 (FTCQ-12). It consist of 12 questions, each rated on a likert-type scale with 7 response options. Lower scores mean a better outcome

    Time frame: Month [2;3]

  3. Evaluate the evolution of Anxiety

    HAD (Hospital Anxiety and Depression Scale) score. Maximum score for each score (total A, total D) =21. Score over 10 definite state of anxiety. Lower scores mean a better outcome

    Time frame: Month [1;2;3]

  4. Evaluate the evolution of nicotine withdrawal symptoms

    MNWS (Minnesota Nicotine Withdrawal Scale) score. It consist of 8 questions, each rated on a likert-type scale with 0-4 response options. Lower scores mean a better outcome.

    Time frame: Month [1;2;3]

  5. Evaluate the evolution of impulsivity

    UPPS (Impulsive Behavior Scale) score. It consist of 20 questions, each rated on a likert-type scale with 1-4 response options. Lower scores mean a better outcome.

    Time frame: Month [1;2;3]

  6. Evaluate the efficacy of the intervention on smoking cessation

    Self reported abstinence or smoking reduction \> or = 50%

    Time frame: Month [1;2;3]

  7. Evaluate the efficacy of the intervention on smoking cessation

    Self reported abstinence or smoking reduction \> or = 50%

    Time frame: Month [6;12]

  8. Evaluate the evolution of Anxiety

    STAI-Y (Form-Y of the State-Trait Anxiety Inventory) score. It consist of two 20-item scales providing separate measures of state and trait anxiety (S-Anxiety and T-Anxiety, respectively). On a 4-point Likert scale (1-4), a score equal to 4 indicates the presence of a higher level of anxiety.

    Time frame: Month [1;2;3]

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2025, 10 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 10 months is below that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 14, 2023
StartActual
Feb 28, 2024
Primary completionEst.
Jan 10, 2025
CompletionEst.
Jan 10, 2026
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06130423
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Feb 28, 2024
Primary completion
Jan 10, 2025 (estimated)
Completion
Jan 10, 2026 (estimated)
Last update
Mar 1, 2024

Study contacts

Claire LAFAY-CHEBASSIER, Dr
Contact
claire.lafay-chebassier@chu-poitiers.fr
05 49 44 38 36 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion